{"id":1012470,"date":"2026-10-22T07:07:00","date_gmt":"2026-10-22T11:07:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/"},"modified":"2026-10-22T07:07:00","modified_gmt":"2026-10-22T11:07:00","slug":"generate-biomedicines-to-participate-in-november-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/","title":{"rendered":"Generate Biomedicines to Participate in November Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SOMERVILLE, Mass., Oct.  22, 2026  (GLOBE NEWSWIRE) &#8212; Generate Biomedicines Inc. (Nasdaq: GENB) (\u201cGenerate\u201d) today announced that members of its management team will participate in presentations at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Guggenheim 3rd Annual Healthcare Innovation Conference, Boston, Massachusetts:\u00a0<\/strong>Monday, Nov. 9 at 1 p.m. ET<\/li>\n<li>\n          <strong>Jefferies Global Healthcare Conference, London, UK: <\/strong>Monday, Nov. 16 at 10:30 a.m. ET<\/li>\n<\/ul>\n<p>\n        <br \/>To access live webcasts of Generate\u2019s presentations, please visit the \u201cEvents &amp; Presentations\u201d page within the Investors section of Generate\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0sIysbaV2HNtaHsJzQoC1uHWRsnbIq2CqByffTQ-TsgyQ9lvrUF7sGX5A5H3B-10f0NW25RzSQwKfQ28tVTGlElTxbCxauaPZiL8Z5ZZW7fpLWj8DnkPRzW-tb5-iAltBLYCW06b5vGwVFQsy7Qx8Q==\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.generatebiomedicines.com<\/a>. A replay of the webcasts will be available on Generate\u2019s website for 90 days following the event.<\/p>\n<p>\n        <strong>About Generate Biomedicines Inc. <\/strong><br \/>\n        <br \/>Generate (Nasdaq: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better drug candidates for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation. Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ctq-7Hf2TbCtuHHSp9WRml1NN3yE20K4Xj1XNx5ekTsDvfP7CQ0LhnQsMd4hjlSSTjy2RAK0wvGbJb4k6ZT2JsWdEi0YfseObMAaMIRhozBnQqBhqtZlaZPkxczTBUjL\" rel=\"nofollow\" target=\"_blank\"><u>www.generatebiomedicines.com<\/u><\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ua6DCif19xmFCXmoVKqh9TIY0SMhX4rcvke-1BlrwdaVBbdt5mjReJHFZmK4_gT8sZv2LiAFmPFABrI7-gkszw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P4xiWMKOQWaKCzJfe6y89w975OjmhXFKRBGFxa9NEIR4PfQaCgjznTfCENtwEsZ2d__5H8S7ZIRLySvlZIZeZVF1rRVF34zy4eIj0Nci0nQboB_tlHxi0Vi7goaCTcq-H1Izz46l2o7n1XTSJWZNMA==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BabbEvn2sPjOKbTbWWvL0W27tCryahJ8TH1CMprxAMuvcYnjvFvbG50gXHYruVOi3vW6UBCwsMT9b3sSI0z53cJtpcPN6OwbrB3cWR5ixYI=\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p>\n        <strong>Digital Media Disclosure <\/strong><br \/>\n        <br \/>From time to time Generate has used, or expects in the future to use, its investor website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U63KabNu1RNqnsIFDr7jjahGjbZBPj7qi1li_fc_FllRRv7IsUBAIDOKRsQAKkI9kE0b5ycnrkgBaLSCPBj7Ux4O-qW6if8wY4D_MXt2ggzwWm5jaOOXX2hljMRon7NE6Ahkv4n02UfZWYPdAEDTHg==\" rel=\"nofollow\" target=\"_blank\"><u>investors.generatebiomedicines.com<\/u><\/a>), the Generate LinkedIn account (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2dC4vhskD-uRHCNjSyBxuCttFJH3znsPPR3_BSsvpMJOuLmfUYC-4wlHOY2yAybiTNaQ96MXH6uYFRzLASFpDNO2AE6XARrqLYTQR1xBXmgxcNfqQIAWV_krUL_b1uMBh-60OIKUvHa6HsjPoEhrJoqIWp7h4odKRa-Je1GHvXI=\" rel=\"nofollow\" target=\"_blank\"><u>linkedin.com\/company\/generate-biomedicines<\/u><\/a>), and the Generate X account (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UyUm7humN55HVxc3JkiVDDmSwjnQT6gr9bSmhNRAsTAWc4lWcmlVbYS36cXg-gI8n1QmzRLz58MtY97WovZgF8f1zOLodmwPlu3oq1w64bM=\" rel=\"nofollow\" target=\"_blank\"><u>@generate_biomed<\/u><\/a>) as means of disclosing information to the public in a broad, nonexclusionary manner, including for purposes of the SEC\u2019s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor the investor website and these social media channels in addition to news releases, SEC filings, public conference calls, and webcasts, as the information posted on them could be material to investors.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements <\/strong><br \/>\n        <br \/>This news release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding Generate\u2019s planned participation in investor conferences; the timing, progress and format of those conferences; the availability and timing of webcasts and archived replays; the advancement of its drug candidates; the expected enhancements, benefits, and potential of The Generate Platform; and other future expectations. In some cases, forward-looking statements can be identified by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d or the negative of these terms or other similar expressions.<\/p>\n<p>These forward-looking statements are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, but not limited to, risks and uncertainties related to Generate\u2019s ability to successfully develop and obtain regulatory approval for its drug candidates; the initiation, design, progress, timing, and results of preclinical studies and clinical trials; Generate\u2019s ability to obtain, maintain, and enforce intellectual property protection; Generate\u2019s dependence on third parties for the manufacture and development of its drug candidates; the impact of competitive products and technologies; Generate\u2019s ability to replicate results from earlier preclinical studies or clinical trials in current or future clinical trials; Generate\u2019s ability to demonstrate that its drug candidates are safe and effective for their proposed indications; Generate\u2019s ability to obtain additional capital to fund its operations; and general economic, industry, and market conditions.<\/p>\n<p>Additional information on these and other risks and uncertainties that could affect Generate\u2019s business, financial condition, and results of operations is included in Generate\u2019s filings with the Securities and Exchange Commission, including its Quarterly Reports. The forward-looking statements in this news release are made as of the date hereof, and Generate undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this news release, except as required by applicable law.<\/p>\n<p>\n        <strong>Generate Media Contact <\/strong><br \/>\n        <br \/>Megan McLaughlin<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rj97vwE_s9enhYfIwrW-zReJipW2kKS3w5PfqiNDOD-Nm7BFbW1chCUvcnz0WGaKMfgQ-tv6bShLhTdaz0FXDvFg5BfTBe0rZtz7ISZkDrLkXNwTfoue1MBm9cBHdPwY\" rel=\"nofollow\" target=\"_blank\">pr@generatebiomedicines.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTRjMmI1ZTAtMjI0ZC00NDgwLWJlNTYtMjk1Y2I3NjRmYjBkLTEzMjM3NDItMjAyNi0xMC0yMi1lbg==\/tiny\/Generate-Biomedicines-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; Generate Biomedicines Inc. (Nasdaq: GENB) (\u201cGenerate\u201d) today announced that members of its management team will participate in presentations at the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference, Boston, Massachusetts:\u00a0Monday, Nov. 9 at 1 p.m. ET Jefferies Global Healthcare Conference, London, UK: Monday, Nov. 16 at 10:30 a.m. ET To access live webcasts of Generate\u2019s presentations, please visit the \u201cEvents &amp; Presentations\u201d page within the Investors section of Generate\u2019s website at https:\/\/investors.generatebiomedicines.com. A replay of the webcasts will be available on Generate\u2019s website for 90 days following the event. About Generate Biomedicines Inc. Generate (Nasdaq: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Generate Biomedicines to Participate in November Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012470","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Generate Biomedicines to Participate in November Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Generate Biomedicines to Participate in November Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; Generate Biomedicines Inc. (Nasdaq: GENB) (\u201cGenerate\u201d) today announced that members of its management team will participate in presentations at the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference, Boston, Massachusetts:\u00a0Monday, Nov. 9 at 1 p.m. ET Jefferies Global Healthcare Conference, London, UK: Monday, Nov. 16 at 10:30 a.m. ET To access live webcasts of Generate\u2019s presentations, please visit the \u201cEvents &amp; Presentations\u201d page within the Investors section of Generate\u2019s website at https:\/\/investors.generatebiomedicines.com. A replay of the webcasts will be available on Generate\u2019s website for 90 days following the event. About Generate Biomedicines Inc. Generate (Nasdaq: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, &hellip; Continue reading &quot;Generate Biomedicines to Participate in November Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-22T11:07:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Generate Biomedicines to Participate in November Investor Conferences\",\"datePublished\":\"2026-10-22T11:07:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/\"},\"wordCount\":714,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/\",\"name\":\"Generate Biomedicines to Participate in November Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=\",\"datePublished\":\"2026-10-22T11:07:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/generate-biomedicines-to-participate-in-november-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Generate Biomedicines to Participate in November Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Generate Biomedicines to Participate in November Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Generate Biomedicines to Participate in November Investor Conferences - Market Newsdesk","og_description":"SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; Generate Biomedicines Inc. (Nasdaq: GENB) (\u201cGenerate\u201d) today announced that members of its management team will participate in presentations at the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference, Boston, Massachusetts:\u00a0Monday, Nov. 9 at 1 p.m. ET Jefferies Global Healthcare Conference, London, UK: Monday, Nov. 16 at 10:30 a.m. ET To access live webcasts of Generate\u2019s presentations, please visit the \u201cEvents &amp; Presentations\u201d page within the Investors section of Generate\u2019s website at https:\/\/investors.generatebiomedicines.com. A replay of the webcasts will be available on Generate\u2019s website for 90 days following the event. About Generate Biomedicines Inc. Generate (Nasdaq: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, &hellip; Continue reading \"Generate Biomedicines to Participate in November Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-22T11:07:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Generate Biomedicines to Participate in November Investor Conferences","datePublished":"2026-10-22T11:07:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/"},"wordCount":714,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/","name":"Generate Biomedicines to Participate in November Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=","datePublished":"2026-10-22T11:07:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg2MyM3OTA5MDg5IzIzMTIxOTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-to-participate-in-november-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Generate Biomedicines to Participate in November Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012470"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012470\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}